USD 3.75
(0.81%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -14.57 Million USD | 47.1% |
2022 | -27.54 Million USD | -130.54% |
2021 | -11.94 Million USD | -150.52% |
2020 | 23.65 Million USD | 50.31% |
2019 | 15.73 Million USD | 122.02% |
2018 | -71.45 Million USD | 25.5% |
2017 | -95.91 Million USD | -167.77% |
2016 | -35.81 Million USD | -987.46% |
2015 | 4.03 Million USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | -17.39 Million USD | -45.99% |
2024 Q1 | -11.91 Million USD | 18.23% |
2023 Q2 | -15.68 Million USD | 48.34% |
2023 Q3 | -19.98 Million USD | -27.37% |
2023 FY | -14.57 Million USD | 47.1% |
2023 Q1 | -30.36 Million USD | -10.25% |
2023 Q4 | -14.57 Million USD | 27.07% |
2022 Q2 | 37.28 Million USD | 139.72% |
2022 FY | -27.54 Million USD | -130.54% |
2022 Q3 | -9.71 Million USD | -126.07% |
2022 Q4 | -27.54 Million USD | -183.41% |
2022 Q1 | 15.55 Million USD | 230.17% |
2021 FY | -11.94 Million USD | -150.52% |
2021 Q4 | -11.94 Million USD | 31.6% |
2021 Q3 | -17.46 Million USD | 53.47% |
2021 Q2 | -37.54 Million USD | -44.72% |
2021 Q1 | -25.93 Million USD | -209.67% |
2020 Q4 | 23.65 Million USD | -57.36% |
2020 Q3 | 55.46 Million USD | 305.65% |
2020 Q2 | -26.97 Million USD | 71.71% |
2020 FY | 23.65 Million USD | 50.31% |
2020 Q1 | -95.33 Million USD | -705.9% |
2019 Q3 | 3.68 Million USD | 122.56% |
2019 Q1 | -37.27 Million USD | 47.83% |
2019 Q4 | 15.73 Million USD | 327.12% |
2019 FY | 15.73 Million USD | 122.02% |
2019 Q2 | -16.33 Million USD | 56.19% |
2018 Q4 | -71.45 Million USD | -29.87% |
2018 Q3 | -55.02 Million USD | 22.76% |
2018 Q2 | -71.23 Million USD | 11.48% |
2018 Q1 | -80.47 Million USD | 16.09% |
2018 FY | -71.45 Million USD | 25.5% |
2017 Q1 | -26.34 Million USD | 26.46% |
2017 Q4 | -95.91 Million USD | 6.25% |
2017 Q3 | -102.3 Million USD | -514.84% |
2017 Q2 | -16.64 Million USD | 36.83% |
2017 FY | -95.91 Million USD | -167.77% |
2016 FY | -35.81 Million USD | -987.46% |
2016 Q4 | -35.81 Million USD | 0.0% |
2015 FY | 4.03 Million USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Esperion Therapeutics, Inc. | 458.69 Million USD | 103.177% |
Theratechnologies Inc. | 24.87 Million USD | 158.59% |
Safety Shot Inc | -2.28 Million USD | -537.899% |
Cosmos Health Inc. | 8.59 Million USD | 269.624% |
Cronos Group Inc. | -663.32 Million USD | 97.803% |
Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 102.338% |
Organogenesis Holdings Inc. | 15.01 Million USD | 197.063% |
Universe Pharmaceuticals INC | 197.2 Thousand USD | 7489.115% |
ProPhase Labs, Inc. | 19.23 Million USD | 175.773% |
Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | -478.254% |
Dynavax Technologies Corporation | 106.63 Million USD | 113.665% |
Radius Health, Inc. | 359.28 Million USD | 104.056% |
China SXT Pharmaceuticals, Inc. | -9.42 Million USD | -54.532% |
Alvotech | 1.06 Billion USD | 101.369% |
Sunshine Biopharma, Inc. | -15.63 Million USD | 6.797% |
Alpha Teknova, Inc. | 1.97 Million USD | 838.197% |
Intra-Cellular Therapies, Inc. | -130.82 Million USD | 88.862% |
SCYNEXIS, Inc. | -19.35 Million USD | 24.693% |
Harrow Health, Inc. | 116.41 Million USD | 112.517% |
Biofrontera Inc. | 4.05 Million USD | 459.27% |
DURECT Corporation | -7.65 Million USD | -90.384% |
Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 56.537% |
ANI Pharmaceuticals, Inc. | 94.2 Million USD | 115.468% |
OptiNose, Inc. | 58.06 Million USD | 125.096% |
RedHill Biopharma Ltd. | -5.18 Million USD | -180.986% |
Aquestive Therapeutics, Inc. | 74.95 Million USD | 119.442% |
Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | 13736.661% |
SIGA Technologies, Inc. | -148.68 Million USD | 90.199% |
Lifecore Biomedical, Inc. | 121.89 Million USD | 111.954% |
Shineco, Inc. | 29.29 Million USD | 149.75% |
Phibro Animal Health Corporation | 454.84 Million USD | 103.204% |
Procaps Group S.A. | 242.93 Million USD | 105.998% |
TherapeuticsMD, Inc. | 3.67 Million USD | 496.194% |
Regencell Bioscience Holdings Limited | -2.9 Million USD | -402.235% |
Viatris Inc. | 17.13 Billion USD | 100.085% |
Sunshine Biopharma, Inc. | -15.63 Million USD | 6.797% |
Rockwell Medical, Inc. | 4.45 Million USD | 427.02% |
Incannex Healthcare Limited | -5.48 Million USD | -165.67% |
Aytu BioPharma, Inc. | -4.87 Million USD | -198.79% |
Tilray Brands, Inc. | 158.97 Million USD | 109.166% |
Collegium Pharmaceutical, Inc. | 435.33 Million USD | 103.347% |
PetIQ, Inc. | 351.93 Million USD | 104.141% |
Silver Spike Investment Corp. | -32.61 Million USD | 55.317% |
Neurocrine Biosciences, Inc. | 177.3 Million USD | 108.219% |
Journey Medical Corporation | -9.7 Million USD | -50.088% |
Alimera Sciences, Inc. | 55.3 Million USD | 126.347% |
Petros Pharmaceuticals, Inc. | -5.06 Million USD | -187.962% |
Assertio Holdings, Inc. | -32.52 Million USD | 55.203% |
Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | -878.826% |
Embecta Corp. | 1.31 Billion USD | 101.111% |
Cyclo Therapeutics, Inc. | -8.21 Million USD | -77.416% |
Procaps Group, S.A. | 242.93 Million USD | 105.998% |
PainReform Ltd. | -7.95 Million USD | -83.296% |
Avadel Pharmaceuticals plc | 4.21 Million USD | 445.554% |
Hempacco Co., Inc. | 13.61 Million USD | 207.032% |
Talphera, Inc. | -5.72 Million USD | -154.711% |
Pacira BioSciences, Inc. | 432.74 Million USD | 103.367% |
Alvotech | 1.06 Billion USD | 101.369% |
Lantheus Holdings, Inc. | -96.71 Million USD | 84.932% |
Kamada Ltd. | -46.43 Million USD | 68.616% |
Indivior PLC | -33.95 Million USD | 57.081% |
Currenc Group, Inc. | -16.57 Million USD | 12.075% |
Evoke Pharma, Inc. | 260.57 Thousand USD | 5692.269% |
Flora Growth Corp. | -713 Thousand USD | -1943.759% |
Cyclo Therapeutics, Inc. | -8.21 Million USD | -77.416% |
Evolus, Inc. | 63.7 Million USD | 122.873% |
HUTCHMED (China) Limited | -197.45 Million USD | 92.62% |
Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 103.041% |
Akanda Corp. | 3.9 Million USD | 473.171% |